Previous 10 | Next 10 |
Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain officers and directors, made materially false and/or misleading statements, as well as failed to disclose ...
2023-11-24 06:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are many ways to approach penny stocks , but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze....
2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...
2023-11-14 14:22:16 ET Gainers: BioCardia ( BCDA ) +170% . reAlpha Tech Corp. ( AIRE ) +119% . Turnstone Biologics Corp ( TSBX ) +75% . Theseus Pharmaceuticals ( THRX ) +49% . American Coastal Insurance Corp ( ACIC ) +38% . M...
2023-11-14 10:27:14 ET BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Conference Call November 14, 2023, 08:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Rob Risinger - Chief Medical Officer of...
2023-11-14 08:17:25 ET More on BioXcel BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel Therapeutics Q3 2023 Earnings Preview BioXcel spikes after mid-stage data for prostate cancer drug Seeking Alpha’s Quant Rating on BioX...
2023-11-14 08:10:54 ET More on pre-market losers Financial information for Collective Audience, Inc. Financial information for E-Home Household For further details see: EJH and CAUD among pre-market losers
2023-11-14 07:15:42 ET More on BioXcel Therapeutics BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel Therapeutics Q3 2023 Earnings Preview BioXcel spikes after mid-stage data for prostate cancer drug Seeking Alpha’s Quant R...
Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable Alzheimer’s disease Potential market opportunity for BXCL501 to include acute treat...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...